Inside Information: 23andMe and Nightingale Health Announce Strategic Collaboration to Pilot Blood Biomarker Panel
Nightingale Health PlcCompany release, inside information28 June 2024 at 2:00 p.m. (EEST) Nightingale Health Plc (“Nightingale Health”), a pioneer in disease risk detection and preventive health (HEL: HEALTH), and 23andMe Holding Co., a leading preventive health and therapeutics company, today announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. Nightingale’s Remote Health Check accurately measures dozens of biomarkers from a single blood sample, including cholesterols,